Cancer: A Systems Biology disease
Introduction
During the micro-evolutionary process of malignant transformation, cancer cells accumulate multiple genetic alterations that provide them with several capabilities (Cahill et al., 1999). The latter include the escape from normal growth control, evasion of the suicidal apoptotic program, induction of sustained angiogenesis, the ability to metastasise, and to invade healthy tissues (Hanahan and Weinberg, 2000). In the past decades, cancer researchers have collected an enormous amount of information about the differences between cancer cells and their healthy counterparts, with the ultimate goal of identifying drug targets. This has, for instance, led to the identification of genes that are causally implicated in human cancer and to the discovery of the mutations in those genes. A cancer gene census was recently compiled (Futreal et al., 2004), which currently contains 300 genes. The vast majority of these genes function in signal transduction processes within or between cells, govern cell cycle progression, apoptosis, angiogenesis, and infiltration (Vogelstein and Kinzler, 2004).
Although knowledge of the molecular cell biology of cancer is enormous, at the same time, the emerging complexity of the entire ‘cancer system’ overwhelms us, leaving an enormous gap in our understanding and predictive power. In this paper, we will discuss aspects of this complexity, and how one can deal with it to answer questions that are relevant for the treatment of cancer.
Section snippets
Zooming in: complex signaling networks
Many signaling molecules (proteins, lipids, and ions) have been identified, and for many, the way they communicate with each other through signal transduction pathways has been elucidated. Signaling pathways consist of multiple sequential events, including covalent modifications (e.g. phosphorylation), recruitment, allosteric activation or inhibition, and binding of proteins (Alberts et al., 2002). The kinetics of these reactions are often non-linear, as a result of the properties of the
Zooming out: complexity increases
The architecture of signal transduction pathways is not where the complexity of cancer ends. Being parts of the cell, signaling networks are affected by additional levels of organization, for instance, as many proteins are not uniformly distributed over the cell. Areas with high protein concentrations might lead to macromolecular crowding (Ellis and Minton, 2003) and cause steep spatial gradients of activated signaling proteins (Brown and Kholodenko, 1999).
Numerous interactions at the
Cancer: a Systems Biology disease
Above, we have discussed that cancer involves a number of molecular processes at the same time. Looking back, it is clear that the interactions of these processes lead to new functionalities that would not otherwise be possible. An example is the formation of a life-threatening tumor requiring the formation of new blood vessels, which requires the cancer cells to become insensitive to growth inhibition and the endothelial cells to become activated to new blood vessel formation. Indeed, cancer
Towards integration
It appears that the many supra-cellular interactions, which add to the intra-cellular signaling, are all at least to some extent relevant for the development of cancer. As more relevant genes, proteins and interactions are being identified, the total picture will continue to grow even more complex. If we also take into account the non-linearity of the biochemical processes and the fact that different processes act on different time scales (signaling, cell cycle, and angiogenic switch), then it
Network-based drug design
The inhibition of enzymes that contribute to aberrant signaling and cancer progression holds promise for the treatment of cancer. Here, one should perhaps also think about a substantial reduction in the rate of tumor progression and metastasis instead of only about a successful total elimination of tumors. Such new therapies could benefit directly from analyzing networks and whole systems, rather than all their individual parts of systems. Which clinically relevant questions may be answered by
Kinase inhibitors: smart drugs?
Conventional cancer treatment relies on surgery, radiotherapy, and chemotherapy (DeVita et al., 2001). The development of rationalized cancer therapy, based on the knowledge of the biology of cancer, may enhance the arsenal of oncologists. Inhibition of constitutive pathways, e.g. by monoclonal antibodies or tyrosine kinase inhibitors, is a strategy that is already employed in clinical trials (Mendelsohn and Baselga, 2000, Sebolt-Leopold, 2000, Shawver et al., 2002). The success of drugs in
References (74)
- et al.
Control analysis of time-dependent metabolic systems
J. Theor. Biol.
(1989) - et al.
Metabolic control analysis of glycolysis in trypanosomes as an approach to improve selectivity and effectiveness of drugs
Mol. Biochem. Parasitol.
(2000) - et al.
Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells
FEBS Lett.
(2000) - et al.
Spatial gradients of cellular phospho-proteins
FEBS Lett.
(1999) - et al.
Genetic instability and Darwinian selection in tumours
Trends Cell Biol.
(1999) Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs
Trends Biochem. Sci.
(1996)Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability
Curr. Opin. Cell Biol.
(2002)Role of angiogenesis in tumor growth and metastasis
Semin. Oncol.
(2002)- et al.
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Cell
(1996) - et al.
The hallmarks of cancer
Cell
(2000)
Mathematical models of protein kinase signal transduction
Mol. Cell
Sensitivity analysis of stoichiometric networks: an extension of metabolic control analysis to non-steady state trajectories
J. Theor. Biol.
Control theory of regulatory cascades
J. Theor. Biol.
Quantification of short term signaling by the epidermal growth factor receptor
J. Biol. Chem.
Kinetics of histone gene expression during early development of Xenopus laevis
J. Theor. Biol.
Simulation model of doxorubicin activity in islets of human breast cancer cells
Biochim. Biophys. Acta
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
Trends Immunol.
Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3
Trends Biochem. Sci.
Control of spatially heterogeneous and time-varying cellular reaction networks: a new summation law
J. Theor. Biol.
Control analysis for autonomously oscillating biochemical networks
Biophys. J.
Smart drugs: tyrosine kinase inhibitors in cancer therapy
Cancer Cell
Mathematical modeling of the regulation of caspase-3 activation and degradation
J. Theor. Biol.
Cell communication
Molecular Biology of the Cell
A computational study of feedback effects on signal dynamics in a mitogen-activated protein kinase (mapk) pathway model
Biotechnol. Prog.
Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis
J. Cell Biol.
Emergent properties of networks of biological signaling pathways
Science
Systems biology in drug discovery
Nat. Biotechnol.
Increasing complexity of Ras signaling
Oncogene
Metabolic control analysis in drug discovery and disease
Nat. Biotechnol.
Mathematical modelling of tumour-induced angiogenesis: network growth and structure
Cancer Treat. Res.
Data-driven computer simulation of human cancer cell
Ann. N. Y. Acad. Sci.
Cell biology: join the crowd
Nature
Vascular endothelial growth factor as a target for anticancer therapy
Oncologist
Building a cellular switch: more lessons from a good egg
Bioessays
A census of human cancer genes
Nat. Rev. Cancer
Cited by (339)
Systems biology tools for the identification of potential drug targets and biological markers effective for cancer therapeutics
2023, Computational Methods in Drug Discovery and Repurposing for Cancer Therapy